We have a Phase 2b in Etoprazine for LID and ADHD, near commercial product with Lympro. The estimated revenue for those 2 products alone are 1.5B+ annually.
My point is Amarantus's pipleline is ahead of Alios and BP is willing to lay out 1.75B for them.